Skip to main content
SUDARSHAN PHARMA INDUSTRIES LIMITED logo

SUDARSHAN PHARMA INDUSTRIES LIMITED — Investor Relations & Filings

Ticker · 543828 ISIN · INE00TV01023 LEI · 89450093T7PA23ZWJX39 BSE.NS Manufacturing
Filings indexed 12 across all filing types
Latest filing 2026-05-30 Regulatory Filings
Country IN India
Listing BSE.NS 543828

About SUDARSHAN PHARMA INDUSTRIES LIMITED

https://www.sudarshanpharma.com

Sudarshan Pharma Industries Limited is a diversified pharmaceutical entity specializing in the manufacturing, sourcing, and distribution of active pharmaceutical ingredients (APIs), specialty chemicals, and pharmaceutical formulations. The company provides a comprehensive range of chemical intermediates and finished dosage forms across various therapeutic categories. Its operational model encompasses contract manufacturing, outsourcing, and the supply of generic medicines to a global clientele. By maintaining an integrated supply chain and technical expertise, the organization facilitates the procurement and production of high-quality chemical components and medicinal products for the healthcare and industrial sectors.

Recent filings

Filing Released Lang Actions
Please find enclosed the Annual Secretarial Compliance Report issued by Mr. Vishal Manseta, Company Secretary in Practice, for the financial year ended 31/March/2026.
Regulatory Filings Classification · 90% confidence The document is an "Annual Secretarial Compliance Report" prepared by a Practicing Company Secretary and submitted to the stock exchange in compliance with SEBI Listing Regulations (Reg. 24A). It does not contain financial statements or substantive financial analysis, but rather is an officer’s certification/attestation on regulatory compliance. Under the Certification Rule, such filings should be classified as a general regulatory/stock-exchange filing rather than as an annual or interim report. Therefore, it falls under Regulatory Filings (RNS).
2026-05-30 English
Please find enclosed herewith the newspaper advertisement for the Postal Ballo Notice dispatched to the shareholders of the Company on 25/May/2026 published in (i) Mumbai Lakshdeep and ....
Regulatory Filings Classification · 65% confidence The document is a brief notice from Sudarshan Pharma to the stock exchange stating that a newspaper advertisement for a Postal Ballot Notice has been published and is being enclosed. It contains no financial statements, no board changes, no voting results, no dividend details, nor is it an AGM presentation or full report. It is an announcement to a regulator about publishing shareholder-related paperwork, which does not fit any specific category other than a general regulatory announcement. Therefore it falls under Regulatory Filings (RNS).
2026-05-26 English
Please find enclosed the Notice of Postal Ballot together with Explanatory Statement benig sent to the members of the Company.
Proxy Solicitation & Information Statement Classification · 85% confidence The document is a formal Notice of Postal Ballot sent to shareholders, containing explanatory statements and resolutions, remote e-voting instructions, and requests members to cast votes electronically. It is not an earnings release, audit report, dividend notice, or results announcement, but rather materials soliciting shareholder votes on special resolutions. This corresponds to Proxy Solicitation & Information Statement (PSI).
2026-05-25 English
We refer to the Corporate Announcement dated May 15, 2026, (Annexure A) setting out fixed conversion rate of Rs.95.93 per US Dollar for FCCB issue. RBI rate as on date of signing subscription ....
Capital/Financing Update Classification · 90% confidence The document is an official disclosure to the stock exchange revising the terms of a Foreign Currency Convertible Bond (FCCB) issue (including updated exchange/conversion rate, issuance size, tenure, coupon, etc.). This is clearly an update on the company’s financing activity and capital structure. It is not an AGM material, annual or interim report, earnings release, management changes, voting results, or share repurchase. It falls under ‘Capital/Financing Update’ (CAP).
2026-05-21 English
The Board of DIrectors at their meeting held today, 21/May/2026, inter alia, approved the following: 1) Migration of equity shares to main Board of BSE and NSE 2) Making Application ....
Regulatory Filings Classification · 85% confidence The document is a letter to the stock exchange under SEBI LODR Regulation 30 announcing the outcome of a Board meeting and various corporate actions (migration of listing, approval of postal ballot notice, e-voting appointments). It is not an annual or interim report, earnings release, proxy statement, or management/board change notice. It is a generic regulatory announcement, so it falls into the Regulatory Filings (RNS) category.
2026-05-21 English
Allotment of USD 10,000,000 8% Senior Unsecured Foreign Currency COnvertible Bonds Due 2029 of the Company.
Capital/Financing Update Classification · 75% confidence The document is an announcement to the stock exchange under SEBI LODR Regulation 30 detailing the board approval and allotment of US$10 million in 8% senior unsecured foreign currency convertible bonds (FCCBs) – a clear update on the company’s fundraising and capital structure change. It is not a financial report itself but a financing transaction announcement.
2026-05-21 English

Browse filings by year

1 year

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.